Review of NICE Technology Appraisal Guidance No.199; Etanercept, Infliximab, and Adalimumab for the treatment of psoriatic arthritis, No.220; Golimumab for the treatment of psoriatic arthritis, and No.340; Ustekinumab for treating active psoriatic arthritis
Proposal to move the existing guidance to the static list - August 2016
The Institute has undertaken work to consider whether sufficient new evidence has emerged for the Appraisal Committee to be asked to undertake a full review appraisal.
There is no new evidence to suggest that the existing recommendations should be updated, and the availability of biosimilars of infliximab and etanercept will not change the recommendations.
Consequently we propose that TA199, TA220, and TA340 should move to the ‘static list’ of technology appraisals.
Topics on the static list may be transferred back to the active list for further appraisal if new evidence becomes available that is likely to have a material effect on the last guidance issued.
NICE is also developing a clinical guideline for spondyloarthritis, which is due to be published in March 2017. The Guideline Development Group will be able to incorporate the recommendations from TA199, TA220 and TA340 if the appraisals move to the ‘static list’.
In order to be completely confident that this is appropriate, we are asking all relevant consultees and commentators, to inform us of any evidence which will help us decide the best way to update this guidance.
Please see appendix A for a full list of the organisations we have contacted.
This page was last updated: 02 August 2016